Veru announces pricing of public offering of common stock

Miami, feb. 17, 2021 (globe newswire) -- veru inc. (nasdaq: veru), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, announced today the pricing of an underwritten public offering of 6,451,613 shares of its common stock at a price to the public of $15.50 per share. the gross proceeds to veru from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $100 million. in addition, veru has granted the underwriters a 30-day option to purchase up to an additional 967,741 shares of common stock at the public offering price, less underwriting discounts and commissions. the offering is expected to close on or about february 22, 2021, subject to the satisfaction of customary closing conditions.
VERU Ratings Summary
VERU Quant Ranking